Platelet transfusions are dosed to raise a low count to a level safe for the clinical situation, whether that is prophylaxis at a low threshold or a higher target before an invasive procedure. This calculator estimates how many adult platelet doses are needed to achieve a chosen increment.
How it works
The desired increment is the gap between where the count is and where you want it to be. That increment has to be delivered across the patient’s whole blood volume, and only part of any transfused dose stays in circulation:
increment (x10^9/L) = target - current
blood volume (L) = weight_kg x 70 mL/kg / 1000
platelets needed = increment x blood_volume / recovery
doses = platelets_needed / platelets_per_doseThe recovery fraction of about 0.67 accounts for the third of platelets normally held in the spleen. One standard adult dose is taken as 3 times 10 to the 11 platelets. The result is rounded up to whole doses because platelet products are issued as discrete units.
Worked example
A 70 kg patient has a count of 15 and you want to reach 50 before a line insertion. The increment is 35, the blood volume is about 4.9 L, and the platelets needed are 35 times 4.9 divided by 0.67, or roughly 256 times 10 to the 9, which is 2.56 times 10 to the 11. Divided by a 3 times 10 to the 11 dose that is well under one dose, so a single adult unit is sufficient. Always confirm the rise with a post-transfusion count, and if the increment is far below prediction, suspect immune refractoriness or ongoing consumption.
Corrected count increment: checking whether the transfusion worked
The corrected count increment (CCI) is a standard way to assess whether a transfused dose had the expected effect, accounting for the patient’s body size and the number of platelets actually given:
CCI = (post count - pre count) x body surface area (m²)
/ (platelets transfused in units of 10^11)A CCI above 7.5 at one hour post-transfusion is generally taken as a satisfactory response. A CCI below 5 on two consecutive transfusions strongly suggests immune refractoriness (most often HLA antibodies) and prompts investigation for HLA-matched or crossmatched platelets.
Body surface area can be estimated from weight and height using standard nomograms; the typical adult of 70 kg and 170 cm has a BSA of roughly 1.8 m².
Clinical thresholds: when to transfuse
Transfusion thresholds vary by clinical context and should always follow local protocol. Illustrative ranges used in many guidelines include:
| Situation | Typical threshold |
|---|---|
| Stable haematology patient, no bleeding | Count below approximately 10 x10^9/L |
| Fever, infection, or planned minor procedure | Count below approximately 20 x10^9/L |
| Lumbar puncture, epidural, or central line | Count may be raised to around 50 x10^9/L |
| Major surgery or neurosurgical procedure | Count may be raised to 80-100 x10^9/L |
These are illustrative thresholds from general guidance, not a substitute for your institution’s transfusion protocol and the responsible clinician’s judgment.
Platelet product types
Platelets are issued as one of two main product types, and their platelet content differs:
Pooled whole-blood concentrates — four to six buffy-coat or PRP-derived concentrates pooled together. A standard UK adult therapeutic dose (ATD) contains at least 240 x10^9 platelets.
Apheresis (single-donor) platelets — collected from one donor via apheresis. A single apheresis unit typically contains at least 240 x10^9 platelets and is equivalent to a pool, but carries a lower donor-exposure risk.
When adjusting the platelets-per-dose field in the calculator, use the actual content from your blood bank’s product specification rather than a generic figure.
What blunts the expected rise
If a post-transfusion count is far below prediction, the most common causes are:
- Consumption — active bleeding, disseminated intravascular coagulation, or sepsis that continues to consume platelets faster than they are replaced.
- Splenic sequestration — splenomegaly traps a larger fraction than the default 33%, effectively reducing the recovery fraction below 0.67.
- Alloimmune refractoriness — HLA or HPA antibodies destroy donor platelets rapidly; a one-hour CCI is diagnostic.
- Product factors — platelets older than four to five days have reduced viability; ABO-incompatible products may have slightly reduced recovery.
Investigate with a one-hour and 24-hour post-transfusion count and a CCI when refractoriness is suspected.